For AML, older age, advanced disease and increased hematopoietic cell transplant comorbidity index (HCT-CI) are associated with worse prognosis following allogeneic hematopoietic cell transplantation (HCT). This single-center retrospective study investigated the influence of pre-transplant characteristics on outcomes of 387 patients undergoing allogeneic HCT for AML in CR1 and CR2. The multivariable analysis model for overall survival (OS) included age (hazard ratio (HR) = 2.24 for ages 31-64 years and HR = 3.23 for age ⩾ 65 years compared with age ⩽ 30 years, P = 0.003), remission status (HR = 1.49 for CR2 compared with CR1, P = 0.005) and HCT-CI score (HR = 1.47 for ⩾ 3 compared with o 3, P = 0.005). Transplant year was significantly associated with OS (P = 0.001) but this did not influence the model. A weighted score was developed with age ⩽ 30, CR1 and HCT-CI score o 3 receiving 0 points each, and CR2 and HCT-CI score ⩾ 3 receiving 1 point each. Ages 31-64 received 2 points, age ⩾ 65 received 3 points. Scores were grouped as follows: scores 0-1 (low risk, n = 36), score 2 (intermediate-low risk, n = 147), score 3 (intermediate-high risk, n = 141) and scores 4-5 (high risk, n = 63) with 3-year OS of 71%, 55%, 42% and 29% for scores 0-1, 2, 3 and 4-5, respectively (P o 0.0001). The score predicted nonrelapse mortality (P = 0.03) but not cumulative incidence of relapse (P = 0.18). This model should be validated for the pre-HCT assessment of AML patients in CR1 and CR2.
INTRODUCTION
One of the greatest challenges in the practice of allogeneic hematopoietic cell transplantation (HCT) is the ability to predict post-transplant outcome based on pre-transplant parameters. Over the years, a variety of prognostic factors have been examined in numerous studies for post-transplant outcome in the treatment of hematological malignancies. For AML in particular, older patient age at transplant seems to be associated with a worse prognosis, particularly for patients not transplanted in first remission. [1] [2] [3] A variety of pre-transplant risk scores have been developed for the purpose of estimating survival post transplant depending on the effect of parameters known to influence outcome. The modified European Group for Blood and Marrow Transplantation risk score was developed for the pre-transplant assessment of patients with acute leukemia and is composed of parameters that include age at transplant as well as remission status. A higher score is associated with inferior overall survival (OS) and increased relapse post transplant. 4, 5 The hematopoietic cell transplant comorbidity index (HCT-CI) is a score based on the calculation of the effect of multiple different comorbidities found to influence nonrelapse mortality (NRM) for patients who undergo HCT for a variety of hematological malignancies. 6 A recent modification of the HCT-CI score has added age at transplant ⩾ 40 years as an additional comorbidity. 7 The prognostic value of the HCT-CI score for allogeneic HCT in AML has been demonstrated in a number of studies. 8, 9 However, a pre-transplant scoring system specific for AML that incorporates significant patient, disease and transplantrelated parameters has not been developed.
The purpose of this single-center retrospective study was to investigate the influence of a variety of pre-transplant characteristics on the survival of 387 patients who underwent allogeneic HCT for AML and to stratify patient risk groups according to the most significant parameters.
PATIENTS AND METHODS

Patients and transplant procedures
The study population consisted of 387 consecutive patients aged 18-71 years (median 50 years) undergoing first allogeneic transplant for AML between January 1999 and June 2013 at the Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Patients who underwent HCT were in first CR (CR1) or second CR (CR2). Details of the patient and transplant characteristics documented are summarized in Table 1 .
Classification of the intensity of conditioning regimen was based on the criteria suggested by the Center for International Blood and Marrow Transplant Research (CIBMTR). 10 The myeloablative conditioning (MAC) regimens were subdivided into two groups: those used from the years 1999 to 2006 included BuCy (busulfan 3.2 mg/kg/day × 4 days, cyclophosphamide 60 mg/kg/day × 2 days) and CyTBI (cyclophosphamide 60 mg/kg/day × 2 days, total body irradiation (TBI) 1200 cGy, given in six fractions). GvHD prophylaxis consisted of cyclosporin A, combined with either methotrexate or mycophenolate mofetil. In vivo T-cell depletion using alemtuzumab or ATG was used in combination with CyA in selected patients undergoing unrelated donor transplantation for GvHD prophylaxis (n = 95, 25% of patients).
Data
Data were collected from the electronic patient record of the hospital retrospectively as well as from the Bone Marrow Transplant Program database. Cytogenetic data at diagnosis were available for 325 patients (84%). Cytogenetic risk at diagnosis was characterized as favorable, intermediate and unfavorable according to the previously described CIBMTR criteria. 11 The HCT-CI score 6 and Karnofsky performance status (KPS) were obtained retrospectively for each patient. This study was approved by the Cancer Registry Data Access Committee (CRDAC) and the Research Ethics Board of the University Health Network/Princess Margaret Cancer Centre.
Definitions of clinical end points OS times were measured from the date of HCT until death from any cause. For OS, surviving patients were censored on the date of their last follow-up. Relapse was defined as ⩾ 5% blasts in a bone marrow aspirate or peripheral blood or the development of extra-medullary leukemia following transplant. NRM was calculated as death without evidence of disease relapse.
Statistical analysis
Patient and disease characteristics were reported using descriptive statistics (counts and percentages). The main outcome variables of interest included OS, cumulative incidence of relapse (CIR) and cumulative incidence of NRM. The time to event was calculated from the date of bone marrow transplant to the date of event or last date of patients known to be alive. Data were updated as of June 2014.
OS rates for each individual variable studied were calculated using Kaplan-Meier survival curve and log-rank test was used for the univariate analysis. For the continuous variable age at transplant and for the ordinal variable HCT-CI score, 6 binary recursive partitioning was first performed and the optimal cutoff value was established for the effect on OS. For age at transplant, initially age ⩽ 30 was determined as the optimal cutoff, whereas further partitioning demonstrated ⩾ 65 years to be the second cutoff value. For the HCT-CI score the optimal cutoff value was o3. Multivariable analysis was performed for OS using the Cox proportional hazard regression model. Variables with a P-value ⩽ 0.15 on univariate analysis for OS were included in the multivariable model, and stepwise selection algorithm was applied for variable selection using P ⩾ 0.05 as a criterion for variable removal. Hazard ratios (HRs) and 95% confidence Age, remission status and HCT-CI influence HCT for AML FV Michelis et al intervals (CIs) were estimated for the significant risk factors and a weighted score was developed, based on the HRs, for the purpose of assigning patients to risk groups. The potential influence of the time period effect on the developed scoring system was assessed, considering year of transplant as an ordinal variable. The developed scoring system was applied in a univariate analysis for the outcomes of CIR and NRM as well, considering competing events and Gray test. For CIR, death was accounted as competing risk, whereas for NRM, relapse was accounted as competing risk. Outcomes at 3 years were calculated in percentages.
Statistical analyses were performed using EZR on R Commander version 1.24. 12 Binary recursive partitioning and concordance probability assessment were performed using the open-source statistical software R version 3.0.3 (The R Foundation for Statistical Computing, Vienna, Austria, 2013).
RESULTS
Patient and transplant characteristics
Baseline patient, disease and transplant-related characteristics are listed in Table 1 . A total of 387 patients aged 18-71 years (median 50 years) underwent allogeneic transplant for AML in CR1 (n = 276) and CR2 (n = 111) using related (n = 224) or unrelated (n = 163) donors. Grafts were bone marrow for 79 patients (20%) and PBSC for 308 patients (80%). Conditioning intensity was myeloablative in 261 patients (67%) and reduced-intensity in 126 patients (33%). Concerning cytogenetic risk according to the CIBMTR criteria, 11 13 patients (3%) presented with favorable, 278 patients (72%) with intermediate and 34 patients (9%) with unfavorable risk cytogenetics. Among the intermediate cytogenetic risk patients, 154 demonstrated normal karyotype; however, a minority had data available on mutational status (FLT3-ITD and NPM1 mutations). De novo AML was originally diagnosed in 283 patients (73%) and secondary AML in 104 patients (27%). Primary induction failure (failure to achieve morphologic CR post induction, requiring re-induction resulting in CR) occurred in 72 patients (19%). Concerning the HCT-CI score, 246 patients (64%) presented with score o3 and 141 patients (36%) with score ⩾ 3. KPS was 100% for 231 patients (60%), 90% for 108 patients (28%) and ⩽ 80% for 48 (12%) patients.
The distribution of the comorbidities that constitute the HCT-CI 6 is summarized in Table 2 .
OS and development of the prognostic score The results of the analysis for OS are presented in Table 3 . Patients transplanted in CR1 experienced superior OS compared with CR2 (3-year OS 51% vs 38%, respectively, P = 0.001). Age at transplant ⩽ 30, 31-64 and ⩾ 65 years demonstrated 3-year OS of 69%, 47% and 29%, respectively (P = 0.002). An HCT-CI score o3 was superior to score ⩾ 3 (3-year OS 52% vs 39%, respectively, P = 0.002), whereas related donor transplant demonstrated marginally superior survival compared with unrelated (3-year OS 52% vs 41%, respectively, P = 0.04). KPS demonstrated marginal influence on OS (3-year OS 52%, 38% and 46% for KPS 100, 90 and ⩽ 80, respectively, P = 0.07). Cytogenetic risk demonstrated a superior survival for the favorable-risk patients; however, this difference was not significant (3-year OS 69%, 47% and 41% for favorable, intermediate and unfavorable risk, respectively, Abbreviations: CI = confidence interval; HCT-CI = hematopoietic cell transplant comorbidity index; HR = hazard ratio; OS = overall survival.
Age, remission status and HCT-CI influence HCT for AML FV Michelis et al P = 0.19). All other variables demonstrated P values 40.15 (Table 3) . The following variables were selected according to the previously described inclusion criteria (P ⩽ 0.15) for the multivariable analysis for OS: remission status, age at transplant, HCT-CI score, donor status and KPS. The final multivariable model for OS is described in Table 4 . This includes age at transplant (HR = 2.24 for ages 31-64 and HR = 3.23 for age ⩾ 65, P = 0.003), remission status (HR = 1.49 for CR2, 95% CI 1.13-1.97, P = 0.005) and HCT-CI score (HR = 1.47 for ⩾ 3, 95% CI 1.12-1.92, P = 0.005) as the remaining significantly independent variables. The analysis was repeated including the time period when the transplant was performed. The year of transplant was examined as an ordinal value and this demonstrated a significant association with OS in the multivariable analysis (P = 0.001). However, this did not influence the remaining three independent prognostic variables as described previously, with minimal effect on the HRs (HR = 2.36 and 3.73 for ages 31-64 and ⩾ 65, respectively, 1.55 for CR2 and 1.44 for HCT-CI score ⩾ 3).
A weighted score was then developed based on the previously described HR values from the multivariable analysis. Accordingly, age ⩽ 30, remission status CR1 and HCT-CI score o3 received 0 points each. Remission status CR2 and HCT-CI score ⩾ 3 received 1 point each. Ages 31-64 received 2 points, whereas age ⩾ 65 received 3 points. Patients thus demonstrated a total score of 0 (n = 24), 1 (n = 12), 2 (n = 147), 3 (n = 141), 4 (n = 58) and 5 (n = 5). The univariate analysis for OS of patients stratified in this manner is depicted in Figure 1 . OS at 3 years post transplant was 66% (±10%), 83% (±11%), 55% (±4%), 42% (±4%), 30% (±6%) and 20% (±18%) for scores 0, 1, 2, 3, 4 and 5, respectively (P o 0.0001) ( Table 5) .
Scores were then grouped in order to increase the numbers of patients with the low-and high-risk scores and simplify the stratification as follows: scores 0-1 (low risk, n = 36), score 2 Figure 1 . OS of 387 patients undergoing allogeneic HCT for AML, stratified by the developed scoring system. Patients demonstrated score 0 (n = 24), score 1 (n = 12), score 2 (n = 147), score 3 (n = 141), score 4 (n = 58) and score 5 (n = 5); P o0.0001. The weighted score was based on hazard ratio values from the multivariable analysis. Age ⩽ 30, remission status CR1 and HCT-CI score o3 received 0 points each; remission status CR2 and HCT-CI score ⩾ 3 received 1 point each; age 31-64 received 2 points, whereas age ⩾ 65 received 3 points. 
and scores 4-5 (high risk, n = 63). Univariate analysis of this grouping demonstrated a 3-year OS (Figure 2 ) of 71% (±8%), 55% (±4%), 42% (±4%) and 29% (±6%) for scores 0-1, 2, 3 and 4-5, respectively (P o0.0001) ( Table 5) Influence of the prognostic score on CIR and NRM The grouped score was assessed for CIR. Three-year CIR was 9%, 18%, 23% and 30% for scores 0-1, 2, 3 and 4-5, respectively (P = 0.18). The score was also assessed for impact on NRM (Figure 3) , with a 3-year NRM of 23%, 29%, 38% and 47% for scores 0-1, 2, 3 and 4-5, respectively (P = 0.03).
In a multivariable analysis for NRM including the grouped score and all other previously described variables (excluding variables already included in the grouped score), the score demonstrated independent prognostic value (P = 0.03) with HR 1.6, 2.0 and 3.2 for scores 2, 3 and 4-5, respectively, compared with scores 0-1.
DISCUSSION
We demonstrate in a single-center cohort of patients undergoing allogeneic HCT for AML that patient age at transplant, remission status and HCT-CI are independent prognostic parameters that can be combined in a score that effectively stratifies patients for OS. The score, when grouped as described previously, produced a low-risk category (scores 0-1), an intermediate-low risk category (score 2), an intermediate-high risk category (score 3) and a highrisk category (scores 4-5) with 3-year OS 71%, 55%, 42% and 29%, respectively. The scoring system was also prognostic of NRM, although for CIR significant differences in the risk groups were not detected in this cohort.
Cytogenetic risk in our cohort was classified using the recently published CIBMTR criteria for post-allogeneic HCT outcome in AML. The study published by Armand et al.
11 demonstrated a significant difference in OS between the favorable, intermediate and unfavorable cytogenetic subgroups. A similar superior survival is seen in the favorable risk group of the cohort presented here (3-year OS 69%); however, due to a small proportion of patients transplanted with favorable karyotype, this difference was not statistically significant. On the other hand, unlike the CIBMTR study, our cohort demonstrated comparable outcome between intermediate-and unfavorable-cytogenetic-risk subgroups. This may be related to the limited size of our single-center cohort, keeping in mind that the CIBMTR classification of cytogenetic risk on post-transplant outcome has not been confirmed in an independent validation study. In the present study, cytogenetic risk was excluded during the course of the multivariable analysis. The risk stratification system that was developed from this analysis is simple to calculate and is based on readily available data for all patients, irrespective of the availability of cytogenetic data. Our proposed scoring system may be used as a readily calculable tool for the prognostication of patients with AML when they initially present to the allogeneic transplant clinic for consultation.
Concerning the parameters that did influence OS and were included in the prognostic model, age at transplant significantly influenced outcome when the optimal cutoff values of 30 and 65 years were used (as described in Patients and Methods). The literature concerning the influence of age at transplant reflects conflicting results, with some studies reporting older age as a negative factor on outcome 5, 13, 14 and others demonstrating lack of significant influence. 15, 16 In the presented weighted model, the patients with ages 31-64 years received 2 points and with age ⩾ 65 years received 3 points, based on the increased risk for OS associated with these values. The impact of remission status at transplant on outcome is also a topic of debate, and there are limited references in the literature that address that issue for AML. The present study demonstrated a significantly worse OS for patients transplanted in CR2 and these patients received a weighted score of 1. The same applies for patients transplanted with an HCT-CI score of ⩾ 3 and this coincides with the published literature concerning HCT-CI for AML, which regards scores ⩾ 3 as belonging to a high-risk group. 8 We recently demonstrated that, for AML patients in particular, low-risk HCT-CI scores could not discriminate a small subgroup of patients with a particularly favorable outcome post transplant. These patients were younger (median age 31 years) and transplanted in CR1 with related donors. 17 Sorror et al. 7 recently reported improved stratification of risk groups for NRM when age at transplant ⩾ 40 years was added to the HCT-CI score as an additional comorbidity, thus developing the HCT-CI/age index. The prognostic scoring system we present, which is specific for AML following HCT, incorporates remission status as an additional risk factor when patients undergo HCT in either CR1 or CR2.
A potential pitfall of this study is the limited number of patients involved, as the study is the result of a single-center experience. Another issue with the study is the long time span involved, during which transplant practices have evolved. We have addressed the latter issue by incorporating the year of transplant into the multivariable analysis, and this did not demonstrate any influence on the prognostic value of the developed scoring system. We must also note that in the present study, cytogenetic risk was classified according to the CIBMTR criteria, 11 which have not been confirmed in an independent validation. Repeat analysis of a larger, independent multicenter data set using the score we have developed would be required in validating the prognostic value of the score.
In conclusion, this study demonstrated that risk stratification for OS for patients undergoing allogeneic HCT for AML is feasible by examining the parameters of age, remission status and HCT-CI comorbidity score. The scoring system developed is simple to calculate for all potential HCT candidates and may be useful in the pre-transplant assessment and consultation of patients. An independent study with a larger cohort of patients would be necessary to confirm these results.
